TY - JOUR
T1 - Pain in amyotrophic lateral sclerosis
AU - Chiò, Adriano
AU - Mora, Gabriele
AU - Lauria, Giuseppe
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients' quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, different treatments have been suggested, ranging from non-steroidal anti-inflammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specific mechanisms and studies of individualised therapies.
AB - Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients' quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, different treatments have been suggested, ranging from non-steroidal anti-inflammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specific mechanisms and studies of individualised therapies.
UR - http://www.scopus.com/inward/record.url?scp=85007613537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007613537&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(16)30358-1
DO - 10.1016/S1474-4422(16)30358-1
M3 - Review article
AN - SCOPUS:85007613537
VL - 16
SP - 144
EP - 157
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 2
ER -